{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Acrylamide : Questions médicales les plus fréquentes",
"headline": "Acrylamide : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Acrylamide : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-03",
"dateModified": "2025-04-28",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Acrylamide"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Acrylamides",
"url": "https://questionsmedicales.fr/mesh/D000178",
"about": {
"@type": "MedicalCondition",
"name": "Acrylamides",
"code": {
"@type": "MedicalCode",
"code": "D000178",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.241.081.069.094"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Acrylamide",
"alternateName": "Acrylamide",
"code": {
"@type": "MedicalCode",
"code": "D020106",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Fang Chen",
"url": "https://questionsmedicales.fr/author/Fang%20Chen",
"affiliation": {
"@type": "Organization",
"name": "College of Food Science and Nutritional Engineering, National Engineering Research Center for Fruit and Vegetable Processing, Key Laboratory of Fruits and Vegetables Processing, Ministry of Agriculture, Engineering Research Centre for Fruits and Vegetables Processing, Ministry of Education, Beijing Key Laboratory for Food Non-thermal Processing, China Agricultural University, Beijing 100083, China. Electronic address: chenfangch@sina.com."
}
},
{
"@type": "Person",
"name": "Katarzyna Petka",
"url": "https://questionsmedicales.fr/author/Katarzyna%20Petka",
"affiliation": {
"@type": "Organization",
"name": "Department of Plant Products Technology and Nutrition Hygiene, Faculty of Food Technology, University of Agriculture in Krakow, 30-149 Kraków, Poland."
}
},
{
"@type": "Person",
"name": "Aleksandra Duda-Chodak",
"url": "https://questionsmedicales.fr/author/Aleksandra%20Duda-Chodak",
"affiliation": {
"@type": "Organization",
"name": "Department of Fermentation Technology and Microbiology, Faculty of Food Technology, University of Agriculture in Krakow, 30-149 Kraków, Poland."
}
},
{
"@type": "Person",
"name": "Milena Bušová",
"url": "https://questionsmedicales.fr/author/Milena%20Bu%C5%A1ov%C3%A1",
"affiliation": {
"@type": "Organization",
"name": "Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic."
}
},
{
"@type": "Person",
"name": "Vladimír Bencko",
"url": "https://questionsmedicales.fr/author/Vladim%C3%ADr%20Bencko",
"affiliation": {
"@type": "Organization",
"name": "Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37511475",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241411715"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.",
"datePublished": "2023-03-07",
"url": "https://questionsmedicales.fr/article/36894035",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1053/j.gastro.2023.02.044"
}
},
{
"@type": "ScholarlyArticle",
"name": "Early detection of cancer therapy cardiotoxicity by radionuclide angiography: An update.",
"datePublished": "2023-02-28",
"url": "https://questionsmedicales.fr/article/36855007",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12350-023-03202-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Optimal age to stop prostate cancer screening and early detection.",
"datePublished": "2023-08-19",
"url": "https://questionsmedicales.fr/article/37598870",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jcpo.2023.100443"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum IgG N-glycans enable early detection and early relapse prediction of colorectal cancer.",
"datePublished": "2022-10-03",
"url": "https://questionsmedicales.fr/article/36121650",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ijc.34298"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Acides carboxyliques",
"item": "https://questionsmedicales.fr/mesh/D002264"
},
{
"@type": "ListItem",
"position": 4,
"name": "Acides acycliques",
"item": "https://questionsmedicales.fr/mesh/D000144"
},
{
"@type": "ListItem",
"position": 5,
"name": "Acrylates",
"item": "https://questionsmedicales.fr/mesh/D000179"
},
{
"@type": "ListItem",
"position": 6,
"name": "Acrylamides",
"item": "https://questionsmedicales.fr/mesh/D000178"
},
{
"@type": "ListItem",
"position": 7,
"name": "Acrylamide",
"item": "https://questionsmedicales.fr/mesh/D020106"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Acrylamide - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Acrylamide",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-01",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Acrylamide",
"description": "Comment détecte-t-on l'exposition à l'acrylamide ?\nQuels tests sont utilisés pour évaluer les effets de l'acrylamide ?\nY a-t-il des symptômes spécifiques à l'intoxication par l'acrylamide ?\nComment évaluer les risques liés à l'acrylamide ?\nQuels professionnels peuvent diagnostiquer l'exposition à l'acrylamide ?",
"url": "https://questionsmedicales.fr/mesh/D020106?mesh_terms=Early+Detection+of+Cancer&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Acrylamide",
"description": "Quels sont les symptômes d'une exposition aiguë à l'acrylamide ?\nL'acrylamide cause-t-il des effets à long terme ?\nY a-t-il des signes de toxicité chronique ?\nLes symptômes varient-ils selon l'exposition ?\nL'acrylamide affecte-t-il le système nerveux ?",
"url": "https://questionsmedicales.fr/mesh/D020106?mesh_terms=Early+Detection+of+Cancer&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Acrylamide",
"description": "Comment réduire l'exposition à l'acrylamide dans l'alimentation ?\nQuels aliments contiennent le plus d'acrylamide ?\nLes réglementations alimentaires limitent-elles l'acrylamide ?\nLes entreprises alimentaires doivent-elles surveiller l'acrylamide ?\nY a-t-il des recommandations pour les consommateurs ?",
"url": "https://questionsmedicales.fr/mesh/D020106?mesh_terms=Early+Detection+of+Cancer&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Acrylamide",
"description": "Quel traitement existe pour l'intoxication par l'acrylamide ?\nComment gérer les symptômes neurologiques liés à l'acrylamide ?\nDes antidotes existent-ils pour l'acrylamide ?\nLes patients doivent-ils être hospitalisés ?\nQuels spécialistes peuvent traiter les effets de l'acrylamide ?",
"url": "https://questionsmedicales.fr/mesh/D020106?mesh_terms=Early+Detection+of+Cancer&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Acrylamide",
"description": "Quelles sont les complications possibles de l'exposition à l'acrylamide ?\nL'acrylamide peut-il causer des cancers ?\nY a-t-il des effets sur la reproduction liés à l'acrylamide ?\nLes effets de l'acrylamide sont-ils réversibles ?\nComment surveiller les complications liées à l'acrylamide ?",
"url": "https://questionsmedicales.fr/mesh/D020106?mesh_terms=Early+Detection+of+Cancer&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Acrylamide",
"description": "Qui est le plus à risque d'exposition à l'acrylamide ?\nLes fumeurs sont-ils plus exposés à l'acrylamide ?\nLes personnes âgées sont-elles plus vulnérables ?\nY a-t-il des prédispositions génétiques à l'acrylamide ?\nLes habitudes alimentaires influencent-elles le risque d'acrylamide ?",
"url": "https://questionsmedicales.fr/mesh/D020106?mesh_terms=Early+Detection+of+Cancer&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment détecte-t-on l'exposition à l'acrylamide ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exposition peut être évaluée par des tests biologiques mesurant l'acrylamide dans l'urine."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les effets de l'acrylamide ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et urinaires peuvent évaluer les niveaux d'acrylamide et ses métabolites."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à l'intoxication par l'acrylamide ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles neurologiques, mais ils ne sont pas spécifiques."
}
},
{
"@type": "Question",
"name": "Comment évaluer les risques liés à l'acrylamide ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation des risques se fait par des études épidémiologiques et des analyses toxicologiques."
}
},
{
"@type": "Question",
"name": "Quels professionnels peuvent diagnostiquer l'exposition à l'acrylamide ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les médecins spécialisés en médecine du travail et en toxicologie peuvent diagnostiquer l'exposition."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une exposition aiguë à l'acrylamide ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des maux de tête, des nausées et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "L'acrylamide cause-t-il des effets à long terme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut entraîner des neuropathies et des effets cancérogènes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes de toxicité chronique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de toxicité chronique incluent des troubles moteurs et des problèmes cognitifs."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'exposition ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent de la durée et du niveau d'exposition à l'acrylamide."
}
},
{
"@type": "Question",
"name": "L'acrylamide affecte-t-il le système nerveux ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'acrylamide peut causer des dommages au système nerveux central et périphérique."
}
},
{
"@type": "Question",
"name": "Comment réduire l'exposition à l'acrylamide dans l'alimentation ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez de cuire les aliments à haute température et privilégiez les méthodes de cuisson douces."
}
},
{
"@type": "Question",
"name": "Quels aliments contiennent le plus d'acrylamide ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les aliments frits, grillés ou cuits au four, comme les pommes de terre, contiennent souvent de l'acrylamide."
}
},
{
"@type": "Question",
"name": "Les réglementations alimentaires limitent-elles l'acrylamide ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs pays ont mis en place des réglementations pour limiter l'acrylamide dans les aliments."
}
},
{
"@type": "Question",
"name": "Les entreprises alimentaires doivent-elles surveiller l'acrylamide ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les entreprises doivent surveiller et réduire les niveaux d'acrylamide dans leurs produits."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les consommateurs ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les consommateurs sont conseillés de diversifier leur alimentation et de limiter les aliments frits."
}
},
{
"@type": "Question",
"name": "Quel traitement existe pour l'intoxication par l'acrylamide ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique, mais des soins symptomatiques peuvent être fournis."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes neurologiques liés à l'acrylamide ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion peut inclure des thérapies physiques et des médicaments pour soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Des antidotes existent-ils pour l'acrylamide ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas d'antidote spécifique pour l'acrylamide, le traitement est symptomatique."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être hospitalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hospitalisation dépend de la gravité des symptômes et de l'exposition à l'acrylamide."
}
},
{
"@type": "Question",
"name": "Quels spécialistes peuvent traiter les effets de l'acrylamide ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les neurologues et les toxicologues sont souvent impliqués dans le traitement des effets de l'acrylamide."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de l'exposition à l'acrylamide ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles neurologiques, des cancers et des problèmes de reproduction."
}
},
{
"@type": "Question",
"name": "L'acrylamide peut-il causer des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'acrylamide est classé comme cancérogène potentiel par certaines agences de santé."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets sur la reproduction liés à l'acrylamide ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que l'acrylamide peut affecter la fertilité et le développement fœtal."
}
},
{
"@type": "Question",
"name": "Les effets de l'acrylamide sont-ils réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains effets peuvent être réversibles, mais d'autres, comme les dommages nerveux, peuvent être permanents."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications liées à l'acrylamide ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance se fait par des examens médicaux réguliers et des évaluations neurologiques."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'exposition à l'acrylamide ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs dans l'industrie chimique et alimentaire sont les plus à risque d'exposition."
}
},
{
"@type": "Question",
"name": "Les fumeurs sont-ils plus exposés à l'acrylamide ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente l'exposition à l'acrylamide en raison de sa présence dans la fumée."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus vulnérables ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent être plus vulnérables aux effets de l'acrylamide en raison de la santé générale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques à l'acrylamide ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines variations génétiques peuvent influencer la métabolisation de l'acrylamide, augmentant le risque."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le risque d'acrylamide ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en aliments frits et grillés augmente le risque d'exposition à l'acrylamide."
}
}
]
}
]
}
The central objective of the metamorphosis of discovery science into biomedical applications is to serve the purpose of patients and curtail the global disease burden. The journey from the discovery o...
Diagnosing gastric cancer (GC) while the disease remains eligible for surgical resection is challenging. In view of this clinical challenge, novel and robust biomarkers for early detection thus improv...
The present 3-step study incorporated data from 2141 patients, including 888 with GC, 158 with chronic atrophic gastritis, 193 with intestinal metaplasia, 501 healthy donors, and 401 with other gastro...
In discovery phase, one LR (GClnc1) was found to be up-regulated in both tissue and circulating EV samples with an area under the curve (AUC) of 0.9369 (95% confidence interval [CI], 0.9073-0.9664) fo...
EV-derived GClnc1 serves as a circulating biomarker for the early detection of GC, thus providing opportunities for curative surgery and improved survival outcomes....
Cancer therapy-induced cardiotoxicity is an emerging clinical and healthcare issue. Myocardial dysfunction and heart failure are mostly responsible for increased cardiovascular mortality in cancer dis...
Prostate Cancer screening should be discontinued at older ages because competing mortality risks eventually dominate the risk of Prostate Cancer and harms exceed benefits. We explored the Prostate Can...
We applied Bellman Equations to formulate the net benefits biopsy and "do nothing". Using difference between the net benefits of two alternatives, we calculated the stopping age. The cancer states wer...
Our results suggested that Prostate Cancer screening stopping ages from the patient, healthcare system, and social were 70, 68, and 68 respectively. The univariate sensitivity analysis showed that the...
Men should not be screened for Prostate Cancer beyond 70 years old, as this results in the net benefit of "do nothing" above the biopsy. Nevertheless, this finding needs to be further studied with mor...
Colorectal cancer (CRC) develops mainly from colorectal advanced adenomas (AA), which are considered precancerous lesions. Novel early diagnostic biomarkers are urgently needed to distinguish CRC and ...
The modality to detect ovarian cancer at an early stage is very limited. Early diagnosis determines the prognosis. This study aimed to develop a risk assessment tool for early detection of ovarian can...
This study was carried out as a cohort study of patients diagnosed with suspected ovarian tumors undergoing cytoreduction operation at Hasan Sadikin Hospital, Bandung, from December 2019 to September ...
In total, 115 patients included in this study. The differences were statistically significant in terms of the six variables (abdominal bloating, nausea/vomiting, decreased of appetite, fullness, menst...
Risk assessments based on ovarian cancer self-assessment unfortunately were not comparable to postoperative histopathology as a single predictor. Ten variables in ovarian cancer artificial intelligenc...
Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness o...
In this research, we harnessed the Mutation Capsule Plus (MCP) technology to profile an array of genomic characteristics from cfDNA procured from a single blood draw. This profiling encompassed DNA me...
This model was subsequently validated in another cohort comprising 89 CRC patients and 95 healthy controls. Remarkably, the model achieved an area under the curve (AUC) of 0.981 (95% confidence interv...
Our findings underscore the clinical potential of our multiomics liquid biopsy test, indicating its prospective role as a noninvasive method for early-stage CRC detection. This multiomics approach hol...
Clinical diagnostics rely heavily on the detection and quantification of cancer biomarkers. The rapid detection of cancer-specific biomarkers is of great importance in the early diagnosis of cancers a...
A cell-free DNA (cfDNA) assay would be a promising approach to early cancer diagnosis, especially for patients with dense tissues. Consistent cfDNA signatures have been observed for many carcinogens. ...
Hepatocellular carcinoma (HCC) is the fastest-rising and fourth most common cause of cancer death worldwide. Liver cirrhosis is the largest underlying risk factor for HCC. Therefore, patients with cir...
This is a UK-based prospective, longitudinal, diagnostic, prognostic, multicentre, non-CTIMP study. Aiming to recruit 3000 patients with liver cirrhosis without a HCC diagnosis, the Pearl cohort will ...
Ethical approval has been granted by REC and the trial is registered on ClinicalTrials.gov. The results will be published in peer-reviewed journals and presented at relevant meetings....
NCT05541601....